[The combined preparation ligentin in the treatment of inflammatory disease of the urogenital organs].
The actuality of the problem is conditioned by the persistence of residual inflammations in a significant number of the patients with urogenital infections after the completion of the etiotropic therapy. The main goal of the study was to develop a method for the treatment of post-gonorrheal and post-chlamydial colpitis, colpomycosis, endocervicitis and urethritis by local application of Ligenten, a gel containing gentamicin, ethonium and lidocaine (as an anesthetic). The trial included 28 females at the age of 20 to 58 years with residual inflammations in the urogenital organs after the completion of the antimicrobial therapy of the urogenital infections. The gel was applied locally as tamponade and/or irrigation of the urethra 1-2 times a day for 6 to 10 days. The results of the treatment showed that the residual inflammations were completely eliminated in 17 out of 26 patients, in 5 patients a significant improvement was stated and in 4 patients the treatment failed. The data indicated that Ligenten is useful in the complex treatment of urogenital infections as a local therapy of residual inflammations.
Kisina
V I
VI
D000328:Adult; D000779:Anesthetics, Local / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D052776:Female Urogenital Diseases / Q000188:drug therapy*; D005782:Gels; D005839:Gentamicins / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D008012:Lidocaine / Q000627:therapeutic use*; D008875:Middle Aged; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*
D000779:Anesthetics, Local; D000890:Anti-Infective Agents; D004338:Drug Combinations; D005782:Gels; D005839:Gentamicins; C089167:Ligenten; D000644:Quaternary Ammonium Compounds; D008012:Lidocaine
Antimikrobnye peptidy i rezistentnost' zhivotnykh.